ReviewFrontiers in immunology2026
T cell exhaustion: a two-sided blade in systemic lupus erythematosus, from molecular mechanisms to clinical translation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulated immune responses and extensive inflammatory damage to several organs are hallmarks of systemic lupus erythematosus (SLE), a highly heterogeneous systemic autoimmune disease that significantly impairs patients' quality of life and prognosis. Persistent antigenic stimulation causes T cell exhaustion (Tex), a unique functional state that is carefully controlled by exogenous, temporal, and spatial factors. Tex plays a special bidirectional regulatory role in SLE: on the one hand, it exerts a protective effect by suppressing the excessive activation of autoreactive T cells, thereby mitigating immune-mediated damage to target organs; on the other hand, abnormal exhaustion of specific T cell subsets leads to a loss of immunoregulatory function and may even promote the secretion of pro-inflammatory cytokines, thereby exacerbating pathological damage. Therapeutic strategies based on this dual mechanism focus on restoring immune homeostasis by enhancing protective exhaustion and inhibiting pathogenic exhaustion processes; this can be achieved through precise regulation of exhausted T cell subsets, improvement of the immune microenvironment, and interventions targeting key signalling pathways. This article provides a systematic review of the core molecular mechanisms and phenotypic characteristics of Tex, highlighting the latest research advances regarding its bidirectional regulatory role in SLE, and discusses in detail relevant diagnostic biomarkers and potential targeted therapeutic strategies. It aims to provide new insights and a theoretical basis for the clinical assessment, personalised treatment, and targeted drug development of SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.